(1R,3R)3-羟基环戊烷羧酸 | 946594-17-8

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 环羧酸
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (1R,3R)3-羟基环戊烷羧酸
• 英文名称: (1R,3R)-3-hydroxy-cyclopentanecarboxylic acid
• 英文别名: (1R,3R)-3-Hydroxycyclopentanecarboxylic acid；(1R,3R)-3-hydroxycyclopentane-1-carboxylic acid
• CAS: 946594-17-8
• 化学式: C₆H₁₀O₃
• 分子量: 130.144
• InChiKey: XWWQLKYMTLWXKN-RFZPGFLSSA-N

物化性质

• 沸点：
  297.2±33.0 °C(Predicted)
• 密度：
  1.328±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-2-amino-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methylbutan-1-one hydrochloric acid salt 、 (1R,3R)3-羟基环戊烷羧酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 BMS-457
  参考文献：
  名称：

  Discovery of the CCR1 Antagonist, BMS-817399, for the Treatment of Rheumatoid Arthritis

  摘要：

  High-affinity, functionally potent, urea-based antagonists of CCR1 have been discovered. Modulation of PXR transactivation has revealed the selective and orally bioavallable CCR1 antagonist BMS-817399 (29), which entered clinical trials for the treatment of rheumatoid arthritis.

  DOI：

  10.1021/jm5003167
• 作为产物：
  描述：

  3-环戊烯甲酸 在 4-二甲氨基吡啶 、 Wilkinson's catalyst 、 氢气 、 palladium(II) hydroxide 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 儿萘酚硼烷 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 (1R,3R)3-羟基环戊烷羧酸
  参考文献：
  名称：

  The discovery of BMS-457, a potent and selective CCR1 antagonist

  摘要：

  A series of compounds which exhibited good human CCR1 binding and functional potency was modified resulting in the discovery of a novel series of high affinity, functionally potent antagonists of the CCR1 receptor. Issues of PXR activity, ion-channel potency, and poor metabolic stability were addressed by the addition of a hydroxyl group to an otherwise lipophilic area in the molecule resulting in the discovery of preclinical candidate BMS-457 for the treatment of rheumatoid arthritis. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.04.079

文献信息

• PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：Carter Percy H.

  公开号：US20070208056A1

  公开（公告）日：2007-09-06

  The present application describes substituted piperidinyl modulators of MIP-1α or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.

  本申请描述了MIP-1α或CCR-1的取代哌啶调节剂或其立体异构体或药学上可接受的盐。此外，还公开了使用上述调节剂治疗和预防炎症性疾病，如哮喘和过敏性疾病，以及自身免疫病理学，如类风湿性关节炎和移植排斥等方法。
• PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：Santella Joseph B.

  公开号：US20100222366A1

  公开（公告）日：2010-09-02

  The present application describes modulators of MIP-1 of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R1, R3, R4, R5, R5a and R5b, are as set forth above. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators are disclosed.

  本申请描述了MIP-1的调节剂，其化学式为(I)：或其立体异构体或药学上可接受的盐，其中m、Q、T、W、Z、R1、R3、R4、R5、R5a和R5b如上所述。此外，还公开了使用这些调节剂治疗和预防炎症性疾病，如哮喘和过敏疾病，以及自身免疫病理，如类风湿性关节炎和动脉粥样硬化的方法。
• [EN] N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE AND N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE DERIVATIVES AS IRAK4 INHIBITORS FOR THE TREATMENT OF ASTHMA<br/>[FR] DÉRIVÉS DE N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE ET DE N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS D'IRAK4 POUR LE TRAITEMENT DE L'ASTHME
  申请人：ASTRAZENECA AB

  公开号：WO2022122876A1

  公开（公告）日：2022-06-16

  The present application relates to a compound of Formula (A),wherein R1 is selected from Formula (II) and Formula (III) and R2 is selected from Formula (IV), Formula (V) and Formula (VI) as IRAK4 inhibitors for use in methods of treatment of e.g. asthma and chronic obstructive pulmonary disease (COPD), cancer, inflammatory diseases, and autoinflammatory/autoimmune diseases such as e.g. systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjogren's syndrome, systemic sclerosis, gout, endometriosis, atopic dermatitis and psoriasis. Preferred compounds of the present invention are e.g.: • N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2H-indazole-5- carboxamide, • N-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2H-indazole-5- carboxamide, • N-(imidazo[1,2-b]pyridazin-3-yl)-1-azaspiro[4.5]decan-8-yl-2H- indazole-5-carboxamide, and • N-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-azaspiro[4.5]decan-8-yl-2H- indazole-5-carboxamide derivatives. An exemplary compound of the present invention is e.g. N- (imidazo[1,2-b]pyridazin-3-yl)-6-methoxy-2-((5r,8r)-1-methyl-2-oxo-1- azaspiro[4.5]decan-8-yl)-2H-indazole-5-carboxamide (Example 1): Formula (VII).

  本申请涉及一种化合物，其化学式为(A)，其中R1从化学式(II)和化学式(III)中选择，R2从化学式(IV)、化学式(V)和化学式(VI)中选择，作为IRAK4抑制剂用于治疗哮喘和慢性阻塞性肺疾病(COPD)、癌症、炎症性疾病以及自身免疫性疾病，如系统性红斑狼疮、类风湿性关节炎、肌炎、干燥综合症、系统性硬化症、痛风、子宫内膜异位症和银屑病等。本发明的优选化合物包括：•N-(咪唑并[1,2-b]吡嗪-3-基)-1-环己基-2H-吲唑-5-羧酰胺、•N-(吡唑并[1,5-a]嘧啶-3-基)-1-环己基-2H-吲唑-5-羧酰胺、•N-(咪唑并[1,2-b]吡嗪-3-基)-1-氮杂螺[4.5]癸烷-8-基-2H-吲唑-5-羧酰胺和•N-(吡唑并[1,5-a]嘧啶-3-基)-1-氮杂螺[4.5]癸烷-8-基-2H-吲唑-5-羧酰胺衍生物。本发明的一种示例化合物是N-(咪唑并[1,2-b]吡嗪-3-基)-6-甲氧基-2-((5r,8r)-1-甲基-2-氧代-1-氮杂螺[4.5]癸烷-8-基)-2H-吲唑-5-羧酰胺(实例1)：化学式(VII)。
• Piperidinyl derivatives as modulators of chemokine receptor activity
  申请人：Bristol-Myers Squibb Company

  公开号：EP2471773A1

  公开（公告）日：2012-07-04

  The present application describes substituted piperidinyl modulators of MIP-1α or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.

  本申请介绍了 MIP-1α 或 CCR-1 的取代哌啶基调节剂或其立体异构体或药学上可接受的盐类。此外，还公开了使用上述调节剂治疗和预防炎症性疾病（如哮喘和过敏性疾病）以及自身免疫性病症（如类风湿性关节炎和移植排斥反应）的方法。
• HYPDH inhibitors and methods of use for the treatment of kidney stones
  申请人：Wake Forest University Health Sciences

  公开号：US10562844B2

  公开（公告）日：2020-02-18

  Provided herein are compounds of Formula (I), Formula (II), and Formula (III), and compositions comprising the same, as well as methods of use thereof for controlling or inhibiting the formation of calcium oxalate kidney stones, inhibiting the production of glyoxylate and/or oxalate, and/or inhibiting hydroxyproline dehydrogenase (HYPDH).

  本文提供了式(I)、式(II)和式(III)化合物和包含这些化合物的组合物，以及其用于控制或抑制草酸钙肾结石的形成、抑制乙醛酸和/或草酸盐的产生和/或抑制羟脯氨酸脱氢酶（HYPDH）的使用方法。